Literature DB >> 6609793

Campylobacter enteritis. A 3-year experience.

V H San Joaquin, D F Welch.   

Abstract

Campylobacter jejuni was isolated from 135 infants and children seen at the Oklahoma Children's Memorial Hospital over a 3-year period. The comparative frequency of isolation of C. jejuni, Salmonella, and Shigella were 1.5 percent, 2.2 percent, and 3.1 percent, respectively. Campylobacter enteritis was most prevalent during the warm months from May to October, peaking in July. Seventy percent of the afflicted children were 2 years old or younger; only 13 percent were older than 5 years. There were the usual clinical presentations (acute onset of diarrhea, fever, abdominal pain, and bloody stools) of Campylobacter enteritis, but other, less common, patterns also were seen. These included chronic diarrhea without significant systemic manifestations; asymptomatic bloody stools, particularly in neonates; and fever and abdominal pain without diarrhea. Severe complications included hemolytic-uremic syndrome, sepsis associated with septic arthritis and osteomyelitis, and failure to thrive.

Entities:  

Mesh:

Year:  1984        PMID: 6609793     DOI: 10.1177/000992288402300601

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  3 in total

1.  Treatment of Campylobacter gastroenteritis.

Authors:  S Ashkenazi; Y Danziger; Y Varsano; J Peilan; M Mimouni
Journal:  Arch Dis Child       Date:  1987-01       Impact factor: 3.791

Review 2.  Estimating the burden of foodborne diseases in Japan.

Authors:  Yuko Kumagai; Stuart Gilmour; Erika Ota; Yoshika Momose; Toshiro Onishi; Ver Luanni Feliciano Bilano; Fumiko Kasuga; Tsutomu Sekizaki; Kenji Shibuya
Journal:  Bull World Health Organ       Date:  2015-06-01       Impact factor: 9.408

3.  Comparative variation within the genome of Campylobacter jejuni NCTC 11168 in human and murine hosts.

Authors:  Dallas K Thomas; Abdul G Lone; L Brent Selinger; Eduardo N Taboada; Richard R E Uwiera; D Wade Abbott; G Douglas Inglis
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.